Healthcare provider profile · identity verified

Rajeshkumar Ramnikbhai Akbari

Internal Medicine · WILLIAMSPORT, IN · NPI 1114413150

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	367	96
Amlodipine Besylate	Amlodipine Besylate	223	64
Albuterol Sulfate Hfa	Albuterol Sulfate	190	71
Levothyroxine Sodium	Levothyroxine Sodium	186	47
Lisinopril	Lisinopril	181	53
Metformin Hcl	Metformin Hcl	176	54
Metoprolol Succinate	Metoprolol Succinate	174	55
Omeprazole	Omeprazole	144	36
Pantoprazole Sodium	Pantoprazole Sodium	135	44
Metoprolol Tartrate	Metoprolol Tartrate	134	28
Januvia	Sitagliptin Phosphate	130	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	130	39
Gabapentin	Gabapentin	129	30
Eliquis	Apixaban	126	30
Cefdinir	Cefdinir	120	96
Glimepiride	Glimepiride	115	25
Jardiance	Empagliflozin	113	23
Furosemide	Furosemide	111	40
Hydrochlorothiazide	Hydrochlorothiazide	102	30
Azithromycin	Azithromycin	98	79
Trazodone Hcl	Trazodone Hcl	95	31
Fluticasone Propionate	Fluticasone Propionate	93	36
Escitalopram Oxalate	Escitalopram Oxalate	91	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	90	78
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	29
Alendronate Sodium	Alendronate Sodium	76	17
Clopidogrel	Clopidogrel Bisulfate	76	19
Tamsulosin Hcl	Tamsulosin Hcl	75	21
Alprazolam	Alprazolam	69	15
Rosuvastatin Calcium	Rosuvastatin Calcium	64	18
Methylprednisolone	Methylprednisolone	63	50
Naproxen	Naproxen	62	38
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	61	19
Doxycycline Hyclate	Doxycycline Hyclate	60	57
Spironolactone	Spironolactone	57	11
Prednisone	Prednisone	56	46
Potassium Chloride	Potassium Chloride	46	19
Breo Ellipta	Fluticasone/Vilanterol	44	13
Venlafaxine Hcl Er	Venlafaxine Hcl	41	suppressed
Losartan Potassium	Losartan Potassium	40	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	38	26
Bupropion Xl	Bupropion Hcl	36	suppressed
Meclizine Hcl	Meclizine Hcl	35	13
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Methocarbamol	Methocarbamol	34	22
Buspirone Hcl	Buspirone Hcl	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	32	suppressed
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	31	28
Ozempic	Semaglutide	31	suppressed
Simvastatin	Simvastatin	31	suppressed
Diclofenac Sodium	Diclofenac Sodium	30	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	29	suppressed
Carvedilol	Carvedilol	29	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	29	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	11
Levemir Flexpen	Insulin Detemir	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	19
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Lorazepam	Lorazepam	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Ketoconazole	Ketoconazole	22	15
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Atenolol	Atenolol	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	18
Famotidine	Famotidine	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Oxcarbazepine	Oxcarbazepine	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Valsartan	Valsartan	17	suppressed
Myrbetriq	Mirabegron	16	suppressed
Torsemide	Torsemide	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Fluconazole	Fluconazole	15	12
Levetiracetam	Levetiracetam	15	suppressed
Primidone	Primidone	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	14	11
Baclofen	Baclofen	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Tramadol Hcl Er	Tramadol Hcl	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	12	suppressed
Calcitriol	Calcitriol	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Glipizide	Glipizide	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Propafenone Hcl	Propafenone Hcl	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Nystatin	Nystatin	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error